Tech Company Financing Transactions

Spero Therapeutics Funding Round

Lundbeckfond Ventures, Atlas Venture and Merck Capital Ventures joined a $30 million Series A venture round for Spero Therapeutics. The round was announced on 6/8/2015.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Series A

Lundbeckfond Ventures (Lead Investor) (Casper Breum)

Atlas Venture (Jean-Francois Formela)

Merck Capital Ventures (Josh Resnick)

SR One Capital Management (Vikas Goyal)

The Kraft Group

Proceeds Purpose
Spero plans to use the proceeds from this financing to advance the Potentiator franchise into clinical development by 2016, progress its anti-virulence program in partnership with Roche through the submission of an Investigational New Drug (IND) application, and develop additional programs in its pipeline focused on unmet medical needs in bacterial infections.

Company Information

Company Status
Mailing Address
675 Massachusetts Ave. 14th Floor
Cambridge, MA 02139
Email Address
Not Recorded
Spero Therapeutics' (Nasdaq: SPRO) vision is to find, develop, and advance groundbreaking therapeutics to meet critical patient needs in infectious disease using a unique business and drug discovery model. Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections.
Spero Therapeutics LinkedIn Company Profile
Social Media
Spero Therapeutics Company Twitter Account
Company News
Spero Therapeutics News
Spero Therapeutics on Facebook
Spero Therapeutics on YouTube

Management Team

Email & Social
Chief Executive Officer
Ankit Mahadevia
  Ankit  Mahadevia LinkedIn Profile  Ankit  Mahadevia Twitter Account  Ankit  Mahadevia News  Ankit  Mahadevia on Facebook
Chief Financial Officer
Joel Sendek
  Joel Sendek LinkedIn Profile  Joel Sendek Twitter Account  Joel Sendek News  Joel Sendek on Facebook
Chief Medical Officer
David Melnick
  David Melnick LinkedIn Profile  David Melnick Twitter Account  David Melnick News  David Melnick on Facebook
Chief Operating Officer
Cristina Larkin
  Cristina Larkin LinkedIn Profile  Cristina Larkin Twitter Account  Cristina Larkin News  Cristina Larkin on Facebook
Chief Scientific Officer
Thomas Parr
  Thomas Parr LinkedIn Profile  Thomas Parr Twitter Account  Thomas Parr News  Thomas Parr on Facebook
VP - Bus. Development
Timothy Keutzer
  Timothy Keutzer LinkedIn Profile  Timothy Keutzer Twitter Account  Timothy Keutzer News  Timothy Keutzer on Facebook
VP - Bus. Development
Scott Peterson
  Scott Peterson LinkedIn Profile  Scott Peterson Twitter Account  Scott Peterson News  Scott Peterson on Facebook
VP - Finance
Steve Garbacz
  Steve Garbacz LinkedIn Profile  Steve Garbacz Twitter Account  Steve Garbacz News  Steve Garbacz on Facebook
VP - R & D
Troy Lister
  Troy Lister LinkedIn Profile  Troy Lister Twitter Account  Troy Lister News  Troy Lister on Facebook
VP - Regulatory Affairs
Carol Waldo
  Carol Waldo LinkedIn Profile  Carol Waldo Twitter Account  Carol Waldo News  Carol Waldo on Facebook



Browse more venture capital transactions:

Prev: 6/8/2015: Colabo venture capital transaction
Next: 6/8/2015: Grabit venture capital transaction


Share this article


Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary